Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ampyra
Pharma
Merz to expand and hunt for more deals after closing Inbrija buy
Equipped with two approved meds from Acorda Therapeutics, Germany’s Merz Therapeutics is kicking its specialty neurology ambitions into high gear.
Fraiser Kansteiner
Jul 11, 2024 4:08pm
Biogen returns ex-U.S. rights of MS drug Fampyra to Acorda
Jan 11, 2024 1:15pm
Slow Inbrija launch forces Acorda to slash $800M sales hopes
Feb 13, 2020 10:52am
Acorda's sales team switches gears to promote Inbrija
Jan 15, 2019 11:20am
Acorda's much-needed Inbrija hits a snag at the FDA
Sep 13, 2018 11:20am
Acorda desperately needs Inbrija nod after appeals loss
Sep 11, 2018 11:54am
